$25m is an average for Phase 2b .. from my limited research .
IMO there will be some sort of partnership struck before the trials begin .
Shared costs or a licensing deal ??
It may depend on whether they go for a trial with the new approved drugs or have a trial with another trialing drug . MM has said she is thinking of polymerase inhibitors . Vertex's Telaprevir is the only approved polymerase . It has some issues with toxicity and I am thinking they may prefer something like one of Gilead/Pharmasset's new unapproved polys in an interferon free 12 or 24 week trial ( with ribavirin ) .
This would then be likely to include shared costs and it suits the current budget . It also goes along with what MM has alluded to in various updates and reports . IMO it will be 100% effective .
We are then free to capital raise later at a higher price for the co-infected trial ( with int/rib ) and for more working capital .
- Forums
- ASX - By Stock
- BIT
- location/location/location
location/location/location, page-45
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.55M |
Open | High | Low | Value | Volume |
2.5¢ | 2.6¢ | 2.5¢ | $23.83K | 953.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 141000 | 2.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.5¢ | 36000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 141000 | 0.024 |
2 | 153913 | 0.023 |
5 | 4220555 | 0.022 |
1 | 250000 | 0.021 |
3 | 250000 | 0.020 |
Price($) | Vol. | No. |
---|---|---|
0.025 | 36000 | 1 |
0.026 | 47379 | 2 |
0.027 | 161989 | 2 |
0.028 | 400000 | 2 |
0.029 | 305600 | 3 |
Last trade - 15.15pm 22/08/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online